|
HEART
Heart failure revascularisation trial
Ongoing trial
 |
Author(s) |
Cleland JGF, Freemantle N, Ball SG, Bonser RS, Camici P, Chattopadhyay S, Dutka D, Eastaugh J, Hampton J, Large S, Norell MS, Pennell DJ, Pepper J, Sanda S, Senior R, Smith D |
 |
Title(s) |
The heart failure revascularisation trial (HEART): rationale, design and methodology |
|
Reference(s) |
Eur J Heart Fail 2003;5:295–303 |
|
Disease |
Heart failure due to coronary artery disease |
|
Purpose |
To determine whether revascularisation improves survival in patients with left ventricular systolic dysfunction and heart failure secondary to coronary artery disease |
|
Study design |
Randomised, open |
|
Follow-up |
Aim 5 years |
|
Patients |
Aim 800 patients (400 revascularisation, 400 no revascularisation), with heart failure requiring chronic diuretic therapy, left ventricular ejection fraction < 35% or wall motion index < 1.2, coronary artery disease, and stress-induced myocardial ischaemia |
|
Treatment regimen |
Revascularisation within 12 weeks of randomisation or no revascularisation |
|
Concomitant therapy |
Optimal medical therapy, which may include diuretics, ACE inhibitors, angiotensin-receptor blockers, beta-blockers, spironolactone and antithrombotic agents. Lipid-lowering agents at the discretion of the physician |
|
Results |
Not yet available |
|
|
|
